Vol. 4 No. 5 (2024): May
Reimbursement Reviews

Odevixibat (Bylvay)

decorative image of the issue cover

Published May 10, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses odevixibat (Bylvay) 200 mcg, 400 mcg, 600 mcg, 1,200 mcg capsules.
  • Indication: For the treatment of pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis.